Barclays
VKTX icon

Barclays’s Viking Therapeutics VKTX Stock Holding History

Barclays’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,400
Closed -$1.29M – 5494
2024
Q3 		$1.29M Buy
+20,400
New +$1.2M ﹤0.01% 3181
2018
Q4 		– Sell
-253,200
Closed -$4.41M – 7364
2018
Q3 		$4.41M Buy
+253,200
New +$3.01M ﹤0.01% 1939

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Barclays's VKTX Position: Q1 2026 in Review

Barclays reduced its Viking Therapeutics (VKTX) stake by 86% in Q1 2026, selling an estimated $14.3M and leaving 70,279 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2269.

Barclays first reported a position in VKTX in Q4 2017 and has held it in 34 quarters since. The position peaked at $18.2M in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Barclays held 70,279 shares of Viking Therapeutics worth $2.29M as of Q1 2026.
  • Barclays sold 446,377 Viking Therapeutics shares in Q1 2026, an estimated $14.3M.
  • Viking Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2269 holding.
  • Barclays first reported a position in Viking Therapeutics in Q4 2017 and has held it in 34 quarters since.
  • Barclays's Viking Therapeutics position peaked at $18.2M in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.